Epigenetic pathways regulating bone homeostasis:Potential targeting for intervention of skeletal disorders

Current Osteoporosis Reports

Volumn 12, Issue 4, 2014, Pages 496-506

  Gordon, Jonathan A R ^a   Montecino, Martin A ^b   Aqeilan, Rami I ^c   Stein, Janet L ^a   Stein, Gary S ^a   Lian, Jane B ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

DNAmethylation; Epigenetic marks in bone; Histonemodifications; miRNA; Osteoblast regulation; Osteosarcoma miRNAs

Indexed keywords

ANTAGOMIR; ANTINEOPLASTIC AGENT; DNA; DNA METHYLTRANSFERASE; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; MICRORNA; MICRORNA 16; MICRORNA 214; MICRORNA 34A; MICRORNA 378; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; OSTEOCALCIN; PROTEIN C JUN; PROTEIN FOS; PROTEIN P53; PROTEIN SWI; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG; UNTRANSLATED RNA; WNT PROTEIN;

ARTICLE; BONE ATROPHY; BONE DEVELOPMENT; BONE DISEASE; BONE METASTASIS; CANCER PROGNOSIS; DISEASE ASSOCIATION; DNA METHYLATION; DNA SEQUENCE; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC REGULATION; GENETIC TRAIT; GENOME IMPRINTING; HISTONE MODIFICATION; HUMAN; MITOSIS; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOPOROSIS; OSTEOSARCOMA; PROTEIN PROCESSING; BONE; BONE TUMOR; GENETIC EPIGENESIS; HOMEOSTASIS; OSTEOBLAST; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BONE AND BONES; BONE DISEASES; BONE NEOPLASMS; EPIGENESIS, GENETIC; HOMEOSTASIS; HUMANS; MICRORNAS; OSTEOBLASTS; OSTEOSARCOMA; SIGNAL TRANSDUCTION;

EID: 84918541907     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-014-0240-1     Document Type: Article

References (132)

1. Kilpinen H, Dermitzakis ET.Genetic and epigenetic contribution to complex traits.Hum Mol Genet.2012;21:R24-8.
2. Butler JS, Koutelou E, Schibler AC, Dent SY.Histone-modifying enzymes:regulators of developmental decisions and drivers of human disease.Epigenomics.2012;4:163-77.
3. Stankov K, Benc D, Draskovic D.Genetic and epigenetic factors in etiology of diabetes mellitus type 1.Pediatrics.2013;132:1112-22.
4. Aslibekyan S, Claas SA, Arnett DK.Clinical applications of epigenetics in cardiovascular disease:the long road ahead.Transl Res.2014.doi:10.1016/j.trsl.2014.04.004.
5. van Dijk SJ, Molloy PL, Varinli H,Morrison JL,Muhlhausler BS.Members of Epi S.Epigenetics and human obesity.Int J Obes (Lond).2014.doi:10.1038/ijo.2014.34.
6. Vrtacnik P, Marc J, Ostanek B.Epigenetic mechanisms in bone.Clin Chem Lab Med.2014;52:589-608.
7. Gamez B, Rodriguez-Carballo E, Ventura F.MicroRNAs and post-transcriptional regulation of skeletal development.J Mol Endocrinol.2014;52:R179-97.
8. Delgado-Calle J, Garmilla P, Riancho JA.Do epigenetic marks govern bone mass and homeostasis? Curr Genomics.2012;13:252-63.
9. Barter MJ, Young DA.Epigenetic mechanisms and non-coding RNAs in osteoarthritis.Curr Rheumatol Rep.2013;15:353.
10. Murr R.Interplay between different epigenetic modifications and mechanisms.Adv Genet.2010;70:101-41.
11. van der Eerden BC.MicroRNAs in the skeleton:cell-restricted or potent intercellular communicators? Arch Biochem Biophys.2014 doi:10.1016/j.abb.2014.04.016.
12. Dong S, Yang B, Guo H, Kang F.MicroRNAs regulate osteogenesis and chondrogenesis.Biochem Biophys Res Commun.2012;418:587-91.
13. Lian JB, Stein GS, van Wijnen AJ, et al.MicroRNA control of bone formation and homeostasis.Nat Rev Endocrinol.2012;8:212-27.
14. Taipaleenmaki H, Bjerre Hokland L, Chen L, Kauppinen S, Kassem M.Mechanisms in endocrinology:micro-RNAs:targets for enhancing osteoblast differentiation and bone formation.Eur J Endocrinol.2012;166:359-71.
15. van Wijnen AJ, van de Peppel J, van Leeuwen JP, et al.MicroRNA functions in osteogenesis and dysfunctions in osteoporosis.Curr Osteoporos Rep.2013;11:72-82.
16. DawsonMA, Kouzarides T.Cancer epigenetics:from mechanism to therapy.Cell.2012;150:12-27.
17. Kohli RM, Zhang Y.TET enzymes, TDG and the dynamics of DNA demethylation.Nature.2013;502:472-9.
18. Lehmann U.Aberrant DNA, methylation of microRNA genes in human breast cancer-a critical appraisal.Cell Tissue Res.2014;356:657-64.
19. Wu L, Zhou H, Zhang Q, et al.DNA methylation mediated by a microRNA pathway.Mol Cell.2010;38:465-75.
20. de Andres MC, Kingham E, Imagawa K, et al.Epigenetic regulation during fetal femur development:DNA methylation matters.PLoS One.2013;8:e54957.
21. Villagra A, Gutierrez J, Paredes R, et al.Reduced CpG methylation is associated with transcriptional activation of the bonespecific rat osteocalcin gene in osteoblasts.J Cell Biochem.2002;85:112-22.
22. Lee JY, Lee YM, Kim MJ, et al.Methylation of the mouse DIx5 and Osx gene promoters regulates cell type-specific gene expression.Mol Cells.2006;22:182-8.
23. Hakelien AM, Bryne JC, Harstad KG, et al.The regulatory landscape of osteogenic differentiation.Stem Cells.2014;32:2780-93.
24. Li J, Zhang N, HuangX, et al.Dexamethasone shifts bonemarrow stromal cells from osteoblasts to adipocytes by C/EBPalpha promoter methylation.Cell Death Dis.2013;4:e832.
25. Prosser DE, Jones G.Enzymes involved in the activation and inactivation of vitamin D.Trends Biochem Sci.2004;29:664-73.
26. Fetahu IS, Hobaus J, Kallay E.Vitamin D and the epigenome.Front Physiol.2014;5:164.
27. Zhou Y, Zhao LJ, Xu X, et al.DNA methylation levels of CYP2R1 and CYP24A1 predict vitamin D response variation.J Steroid Biochem Mol Biol.2014;144PA:207-14.
28. Subramaniam D, Thombre R, Dhar A, Anant S.DNA methyltransferases:a novel target for prevention and therapy.Front Oncol.2014;4:80.
29. Richardson BC, Patel DR.Epigenetics in 2013.DNA methylation and miRNA-key roles in systemic autoimmunity.Nat Rev Rheumatol.2014;10:72-4.
30. Jeffries MA, Donica M, Baker L, et al.Genome-wide DNA methylation study identifies significant epigenomic changes in osteoarthritic cartilage.Arthritis Rheumatol.2014.doi:10.1002/art.38762.
31. Delgado-Calle J, Fernandez AF, Sainz J, et al.Genome-wide profiling of bone reveals differentially methylated regions in osteoporosis and osteoarthritis.Arthritis Rheum.2013;65:197-205.
32. BarterMJ, Bui C, Young DA.Epigenetic mechanisms in cartilage and osteoarthritis:DNA methylation, histone modifications and microRNAs.Osteoarthritis Cartilage.2012;20:339-49.
33. Hashimoto K, Otero M, Imagawa K, et al.Regulated transcription of human matrix metalloproteinase 13 (MMP13) and interleukin-1beta (IL1B) genes in chondrocytes depends on methylation of specific proximal promoter CpG sites.J Biol Chem.2013;288:10061-72.
34. Imagawa K, de Andres MC, Hashimoto K, et al.Reduced type IX collagen gene expression in human osteoarthritic chondrocytes is associated with epigenetic silencing by DNA hypermethylation.Arthritis Rheumatol.2014.doi:10.1002/art.38774.
35. Hargreaves DC, Crabtree GR.ATP-dependent chromatin remodeling:genetics, genomics and mechanisms.Cell Res.2011;21:396-420.
36. Gutierrez J, Paredes R, Cruzat F, et al.Chromatin remodeling by SWI/SNF results in nucleosome mobilization to preferential positions in the rat osteocalcin gene promoter.J Biol Chem.2007;282:9445-57.
37. Montecino M, Lian J, Stein G, Stein J.Changes in chromatin structure support constitutive and developmentally regulated transcription of the bone-specific osteocalcin gene in osteoblastic cells.Biochemistry.1996;35:5093-102.
38. Kimura H.Histone modifications for human epigenome analysis.J Hum Genet.2013;58:439-45.
39. Bernstein BE, Mikkelsen TS, Xie X, et al.A bivalent chromatin structure marks key developmental genes in embryonic stem cells.Cell.2006;125:315-26.
40. Ye L, Fan Z, Yu B, et al.Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs.Cell Stem Cell.2012;11:50-61.
41. Vega RB, Matsuda K, Oh J, et al.Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis.Cell.2004;119:555-66.
42. Razidlo DF,Whitney TJ, Casper ME, et al.Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat.PLoS One.2010;5:e11492.
43. Zhou S, Geng S, Glowacki J.Histone deacetylation mediates the rejuvenation of osteoblastogenesis by the combination of 25(OH)D3 and parathyroid hormone in MSCs from elders.J Steroid Biochem Mol Biol.2013;136:156-9.
44. Hu X, Zhang X, Dai L, et al.Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner.Stem Cells Dev.2013;22:248-55.
45. Bradley EW, McGee-Lawrence ME, Westendorf JJ.Hdacmediated control of endochondral and intramembranous ossification.Crit Rev Eukaryot Gene Expr.2011;21:101-13.
46. Zhu ED, Demay MB, Gori F.Wdr5 is essential for osteoblast differentiation.J Biol Chem.2008;283:7361-7.
47. Sinha KM, Yasuda H, Coombes MM, Dent SY, de Crombrugghe B.Regulation of the osteoblast-specific transcription factor Osterix by NO66, a Jumonji family histone demethylase.EMBO J.2010;29:68-79.
48. Hemming S, Cakouros D, Isenmann S, et al.EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.Stem Cells.2014;32:802-15.
49. Young DW, Pratap J, Javed A, et al.SWI/SNF chromatin remodeling complex is obligatory for BMP2-induced, Runx2-dependent skeletal gene expression that controls osteoblast differentiation.J Cell Biochem.2005;94:720-30.
50. Cruzat F, Henriquez B, Villagra A, et al.SWI/SNF-independent nuclease hypersensitivity and an increased level of histone acetylation at the P1 promoter accompany active transcription of the bone master gene Runx2.Biochemistry.2009;48:7287-95.
51. Montecino M, Stein JL, SteinGS, et al.Nucleosome organization and targeting of SWI/SNF chromatin-remodeling complexes:contributions of the DNA sequence.Biochem Cell Biol.2007;85:419-25.
52. Wu H, Whitfield TW, Gordon JA, et al.Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis.Genome Biol.2014;15:R52.Identified Runx2 binding to genomic DNA that discovered hundreds of Runx2 target genes related to epigenetic levels of control during stages of osteoblast differentiation.The complete data set serve as a valuable resource for investigators.
53. Djebali S, Davis CA, Merkel A, et al.Landscape of transcription in human cells.Nature.2012;489:101-8.
54. Ling H, Fabbri M, Calin GA.MicroRNAs and other non-coding RNAs as targets for anticancer drug development.Nat Rev Drug Discov.2013;12:847-65.
55. Cech TR, Steitz JA.The noncoding RNA revolution-trashing old rules to forge new ones.Cell.2014;157:77-94.
56. Flynn RA, Chang HY.Long noncoding RNAs in cell-fate programming and reprogramming.Cell Stem Cell.2014;14:752-61.
57. Ha M, Kim VN.Regulation of microRNA biogenesis.Nat Rev Mol Cell Biol.2014;15:509-24.
58. Vance KW, Ponting CP.Transcriptional regulatory functions of nuclear long noncoding RNAs.Trends Genet.2014;30:348-55.
59. Orom UA, Shiekhattar R.Long noncoding RNAs usher in a new era in the biology of enhancers.Cell.2013;154:1190-3.
60. Lee JT, Bartolomei MS.X-inactivation, imprinting, and long noncoding RNAs in health and disease.Cell.2013;152:1308-23.
61. Paci P, Colombo T, Farina L.Computational analysis identifies a sponge interaction network between long non-coding RNAs and messenger RNAs in human breast cancer.BMCSyst Biol.2014;8:83.
62. Zhu L, Xu PC.Downregulated LncRNA-ANCR promotes osteoblast differentiation by targeting EZH2 and regulating Runx2 expression.Biochem Biophys Res Commun.2013;432:612-7.
63. Dey BK, Pfeifer K, Dutta A.The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration.Genes Dev.2014;28:491-501.
64. Li L, Liu B, Wapinski OL, et al.Targeted disruption of Hotair leads to homeotic transformation and gene derepression.Cell Rep.2013;5:3-12.
65. Dasen JS.Long noncoding RNAs in development:solidifying the Lncs to Hox gene regulation.Cell Rep.2013;5:1-2.
66. Young DW, Hassan MQ, Pratap J, et al.Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2.Nature.2007;445:442-6.
67. Zaidi SK, Grandy RA, Lopez-Camacho C, et al.Bookmarking target genes in mitosis:a shared epigenetic trait of phenotypic transcription factors and oncogenes? Cancer Res.2014;74:420-5.
68. Sarge KD, Park-Sarge OK.Gene bookmarking:keeping the pages open.Trends Biochem Sci.2005;30:605-10.
69. Zaidi SK, Young DW, Javed A, et al.Nuclear microenvironments in biological control and cancer.Nat Rev Cancer.2007;7:454-63.
70. Esquela-Kerscher A, Slack FJ.Oncomirs-microRNAs with a role in cancer.Nat Rev Cancer.2006;6:259-69.
71. Calin GA, Croce CM.MicroRNA signatures in human cancers.Nat Rev Cancer.2006;6:857-66.
72. Ell B, Qiu Q, Wei Y, et al.The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasissuppressive gene prosaposin.J Biol Chem.2014;289:21888-95.
73. Browne G, Taipaleenmaki H, Stein GS, Stein JL, Lian JB.MicroRNAs in the control of metastatic bone disease.Trends Endocrinol Metab.2014;25:320-7.
74. Croset M, Santini D, Iuliani M, et al.MicroRNAs and bone metastasis:a new challenge.Molecules.2014;19:10115-28.
75. Zhou G, Shi X, Zhang J, Wu S, Zhao J.MicroRNAs in osteosarcoma:from biological players to clinical contributors, a review.J Int Med Res.2013;41:1-12.
76. Bi C, ChngWJ.MicroRNA:important player in the pathobiology of multiple myeloma.Biomed Res Int.2014;2014:521586.
77. Gaur T, Hussain S, Mudhasani R, et al.Dicer inactivation in osteoprogenitor cells compromises fetal survival and bone formation, while excision in differentiated osteoblasts increases bone mass in the adult mouse.Dev Biol.2010;340:10-21.
78. Hassan MQ, Maeda Y, Taipaleenmaki H, et al.miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells.J Biol Chem.2012;287:42084-92.
79. Zhang J, Tu Q, Bonewald LF, et al.Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1.J Bone Miner Res.2011;26:1953-63.
80. Liu H, Sun Q,Wan C, Li L, Zhang L, Chen Z.MicroRNA-338-3p regulates osteogenic differentiation of mouse bone marrow stromal stem cells by targeting Runx2 and Fgfr2.J Cell Physiol.2014;229:1494-502.
81. Zhang Y, Xie RL, Croce CM, et al.A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2.Proc Natl Acad Sci U S A.2011;108:9863-8.
82. Baglio SR, Devescovi V, Granchi D, Baldini N.MicroRNA expression profiling of human bone marrow mesenchymal stem cells during osteogenic differentiation reveals Osterix regulation by miR-31.Gene.2013;527:321-31.
83. Jia J, Tian Q, Ling S, Liu Y, Yang S, Shao Z.miR-145 suppresses osteogenic differentiation by targeting Sp7.FEBS Lett.2013;587:3027-31.
84. Li E, Zhang J, Yuan T, Ma B.MiR-143 suppresses osteogenic differentiation by targeting Osterix.Mol Cell Biochem.2014;390:69-74.
85. Chen Q, Liu W, Sinha KM, Yasuda H, de Crombrugghe B.Identification and characterization of microRNAs controlled by the osteoblast-specific transcription factor Osterix.PLoS One.2013;8:e58104.
86. Wang X, Guo B, Li Q, et al.miR-214 targets ATF4 to inhibit bone formation.Nat Med.2013;19:93-100.Demonstrated the therapeutic effectiveness of antagomiR delivery to osteoblasts in vivo to prevent bone loss in mouse models of osteoporosis.
87. Deng Y, Zhou H, Zou D, et al.The role of miR-31-modified adipose tissue-derived stem cells in repairing rat critical-sized calvarial defects.Biomaterials.2013;34:6717-28.
88. Hassan MQ, Gordon JA, BelotiMM, et al.A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program.Proc Natl Acad Sci U S A.2010;107:19879-84.
89. Li Z, Hassan MQ, Jafferji M, et al.Biological functions of miR- 29b contribute to positive regulation of osteoblast differentiation.J Biol Chem.2009;284:15676-84.
90. Sugatani T, Vacher J, Hruska KA.A microRNA expression signature of osteoclastogenesis.Blood.2011;117:3648-57.
91. Kapinas K, Delany AM.MicroRNA biogenesis and regulation of bone remodeling.Arthritis Res Ther.2011;13:220.
92. Li Z, Hassan MQ, Volinia S, et al.A microRNA signature for a BMP2-induced osteoblast lineage commitment program.Proc Natl Acad Sci U S A.2008;105:13906-11.
93. Wang J, Greene SB, Bonilla-Claudio M, et al.Bmp signaling regulates myocardial differentiation from cardiac progenitors through a MicroRNA-mediated mechanism.Dev Cell.2010;19:903-12.
94. Berendsen AD, Olsen BR.Osteoblast-adipocyte lineage plasticity in tissue development, maintenance and pathology.Cell Mol Life Sci.2014;71:493-7.
95. Kawai M, de Paula FJ, Rosen CJ.New insights into osteoporosis:the bone-fat connection.J Intern Med.2012;272:317-29.
96. Liao L, Yang X, Su X, et al.Redundant miR-3077-5p and miR- 705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrow.Cell Death Dis.2013;4:e600.
97. Huang S,Wang S, Bian C, et al.Upregulation ofmiR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression.Stem Cells Dev.2012;21:2531-40.
98. Huang J, Zhao L, Xing L, Chen D.MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation.Stem Cells.2010;28:357-64.
99. Gamez B, Rodriguez-Carballo E, Bartrons R, Rosa JL, Ventura F.MicroRNA-322 (miR-322) and its target protein Tob2 modulate Osterix (Osx) mRNA stability.J Biol Chem.2013;288:14264-75.
100. Yang L, Cheng P, Chen C, et al.miR-93/Sp7 function loop mediates osteoblast mineralization.J Bone Miner Res.2012;27:1598-606.
101. Vimalraj S, Partridge NC, Selvamurugan N.A positive role of microRNA-15b on regulation of osteoblast differentiation.J Cell Physiol.2014;229:1236-44.
102. Finnegan EF, Pasquinelli AE.MicroRNA biogenesis:regulating the regulators.Crit Rev Biochem Mol Biol.2013;48:51-68.
103. Gromak N.Intronic microRNAs:a crossroad in gene regulation.Biochem Soc Trans.2012;40:759-61.
104. Baer C, Claus R, Plass C.Genome-wide epigenetic regulation of miRNAs in cancer.Cancer Res.2013;73:473-7.
105. Li H, Xie H, Liu W, et al.A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans.J Clin Invest.2009;119:3666-77.
106. Lei SF, Papasian CJ, Deng HW.Polymorphisms in predicted miRNA binding sites and osteoporosis.J Bone Miner Res.2011;26:72-8.
107. HassanMQ, Tare R, Lee SH, et al.HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes.Mol Cell Biol.2007;27:3337-52.
108. Gordon JA, HassanMQ, Saini S, et al.Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors.Mol Cell Biol.2010;30:3531-41.
109. Chen C, Cheng P, Xie H, et al.MiR-503 regulates osteoclastogenesis via targeting RANK.J Bone Miner Res.2014;29:338-47.
110. Wang Y, Li L, Moore BT, et al.MiR-133a in human circulating monocytes:a potential biomarker associated with postmenopausal osteoporosis.PLoS One.2012;7:e34641.
111. Seeliger C, Karpinski K, Haug AT, et al.Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures.J Bone Miner Res.2014;29:1718-28.
112. Sugatani T, Hruska KA.Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis.J Cell Biochem.2013;114:1217-22.
113. Ell B, Mercatali L, Ibrahim T, et al.Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis.Cancer Cell.2013;24:542-56.First study highlights the translational potential of miRNAs associated with osteoclasts to inhibit metastatic bone disease by systemic delivery in mouse models of tumor growth in bone.
114. Krzeszinski JY, Wei W, Huynh H, et al.miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.Nature.2014;512:431-5.
115. Luetke A, Meyers PA, Lewis I, Juergens H.Osteosarcoma treatment- where do we stand? A state of the art review.Cancer Treat Rev.2014;40:523-32.
116. Zhou W, Hao M, Du X, Chen K, Wang G, Yang J.Advances in targeted therapy for osteosarcoma.Discov Med.2014;17:301-7.
117. Mutsaers AJ,Walkley CR.Cells of origin in osteosarcoma:mesenchymal stem cells or osteoblast committed cells? Bone.2014;62:56-63.
118. Mortus JR, Zhang Y, Hughes DP.Developmental pathways hijacked by osteosarcoma.Adv Exp Med Biol.2014;804:93-118.
119. Brennecke P, Arlt MJ, Campanile C, et al.CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice.Clin Exp Metastasis.2014;31:339-49.
120. Martin JW, ZielenskaM, Stein GS, vanWijnen AJ, Squire JA.The Role of RUNX2 in Osteosarcoma Oncogenesis.Sarcoma.2011;2011:282745.
121. Sadikovic B, Thorner P, Chilton-Macneill S, et al.Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.BMC Cancer.2010;10:202.
122. van der Deen M, Akech J, Lapointe D, et al.Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility.J Biol Chem.2012;287:4503-17.
123. Pereira BP, Zhou Y, Gupta A, et al.Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1).J Cell Physiol.2009;221:778-88.
124. Yang J, Zhao L, Tian W, et al.Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma.BMC Med Genomics.2013;6:56.
125. DelMare S, Kurek KC, Stein GS, Lian JB, Aqeilan RI.Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma.Am J Cancer Res.2011;1:585-94.
126. Kurek KC, Del Mare S, Salah Z, et al.Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.Cancer Res.2010;70:5577-86.
127. Aqeilan RI, Hassan MQ, de Bruin A, et al.The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism.J Biol Chem.2008;283:21629-39.
128. Miao J, Wu S, Peng Z, Tania M, Zhang C.MicroRNAs in osteosarcoma:diagnostic and therapeutic aspects.Tumor Biol.2013;34:2093-8.
129. Liang W, Gao B, Fu P, Xu S, Qian Y, Fu Q.The miRNAs in the pathogenesis of osteosarcoma.Front Biosci (Landmark Ed).2013;18:788-94.
130. Jones KB, Salah Z, Del Mare S, et al.miRNA signatures associate with pathogenesis and progression of osteosarcoma.Cancer Res.2012;72:1865-77.
131. Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire JA.Analysis of miRNA-gene expressiongenomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma.Cancer Genet.2011;204:138-46.
132. Ouyang L, Liu P, Yang S, Ye S, Xu W, Liu X.A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma.Med Oncol.2013;30:340.